dxy

赵毅教授：Efficacy and safety of brivanib as frist-line or second-line therapy in Asian and non-Asian patients with advanced hepatocellular carcinoma(HCC)：Outcomes from a phase 2 study and a retrospective analysis using modified RECIST criteria for HCC

转载请注明来自丁香园

发布日期: 2010-09-18 13:43	文章来源: 丁香园
点击次数：

Efficacy and safety of brivanib as frist-line or second-line therapy in Asian and non-Asian patients with advanced hepatocellular carcinoma(HCC)：Outcomes from a phase 2 study and a retrospective analysis using modified RECIST criteria for HCC

赵毅教授台北荣民医院

赵毅教授主题讲座

下一页 >

分页: [1] 　 [2 ] 　 [3 ] 　


	以下网友留言只代表网友个人观点，不代表网站观点